Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

(2016) Jianjun Gao et al.   CELL

TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors

(2016) Elien M. Doorduijn et al.   JOURNAL OF CLINICAL INVESTIGATION

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2R null Immunodeficient Mice

(2015) M. F. Sanmamed et al.   CANCER RESEARCH

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy

(2015) Chien-Chung Chang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes

(2015) Cyrille J. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

CD8+CD103+Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients

(2015) Fayçal Djenidi et al.   JOURNAL OF IMMUNOLOGY

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

(2015) David M. Barrett et al.   JOURNAL OF IMMUNOLOGY

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

(2015) B. M. Carreno et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Exome Sequencing to Predict Neoantigens in Melanoma

(2015) A. L. Pritchard et al.   Cancer Immunology Research

Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions

(2014) Y.-C. Lu et al.   CLINICAL CANCER RESEARCH

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

(2014) E. Tran et al.   SCIENCE

TAP expression level in tumor cells defines the nature and processing of MHC class I peptides for recognition by tumor-specific cytotoxic T lymphocytes

(2013) Faten El Hage et al.   Annals of the New York Academy of Sciences

Adjuvants That Improve the Ratio of Antigen-Specific Effector to Regulatory T Cells Enhance Tumor Immunity

(2013) R. Perret et al.   CANCER RESEARCH

Exploiting the curative potential of adoptive T-cell therapy for cancer

(2013) Christian S. Hinrichs et al.   IMMUNOLOGICAL REVIEWS

New Role of Signal Peptide Peptidase To Liberate C-Terminal Peptides for MHC Class I Presentation

(2013) C. C. Oliveira et al.   JOURNAL OF IMMUNOLOGY

Identification of new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from neuritin

(2013) Zhao Yang et al.   JOURNAL OF NEURO-ONCOLOGY

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

(2013) Paul F Robbins et al.   NATURE MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes

(2011) Michael S. Leibowitz et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Different Expression Levels of the TAP Peptide Transporter Lead to Recognition of Different Antigenic Peptides by Tumor-Specific CTL

(2011) A. Durgeau et al.   JOURNAL OF IMMUNOLOGY

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Eeyarestatin 1 Interferes with Both Retrograde and Anterograde Intracellular Trafficking Pathways

(2011) Mina-Olga Aletrari et al.   PLoS One

CD8+ T Cell Responses against TAP-Inhibited Cells Are Readily Detected in the Human Population

(2010) M. H. Lampen et al.   JOURNAL OF IMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Novel Cancer Vaccine Strategy Based on HLA-A*0201 Matched Allogeneic Plasmacytoid Dendritic Cells

(2010) Caroline Aspord et al.   PLoS One

The ERAD Inhibitor Eeyarestatin I Is a Bifunctional Compound with a Membrane-Binding Domain and a p97/VCP Inhibitory Group

(2010) Qiuyan Wang et al.   PLoS One

Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention

(2009) K. Franciszkiewicz et al.   CANCER RESEARCH

Genetic Variants in TAP Are Associated with High-Grade Cervical Neoplasia

(2009) M. H. Einstein et al.   CLINICAL CANCER RESEARCH

The nonpolymorphic MHC Qa-1bmediates CD8+T cell surveillance of antigen-processing defects

(2009) Cláudia C. Oliveira et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Inhibition of p97-dependent Protein Degradation by Eeyarestatin I

(2008) Qiuyan Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

One step at a time: endoplasmic reticulum-associated degradation

(2008) Shruthi S. Vembar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway

(2008) F. El Hage et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA